Epitalon (also written Epithalon, Epitalone) is a synthetic tetrapeptide first described by Russian researcher Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its sequence — Ala-Glu-Asp-Gly — is short, but the research corpus around it spans telomerase activation, pineal function, and longevity models. This article maps what the literature actually shows.
Origin and sequence
Epitalon is a synthetic analogue of epithalamin, a polypeptide extract from bovine pineal gland. The four-amino-acid sequence (Ala-Glu-Asp-Gly) is the minimal active fragment identified through Khavinson’s research programme. Synthesis is straightforward solid-phase peptide synthesis (SPPS).
Telomerase activation claims
The most-cited research finding is that Epitalon increases telomerase activity in human somatic cells in vitro. Khavinson et al. (2003) reported telomerase activity restoration in human fibroblast cultures with concurrent telomere elongation observed over multiple passages.
The mechanism proposed is upregulation of the telomerase catalytic subunit (TERT) at the transcriptional level. This has not been independently replicated outside the Russian research programme to the same magnitude, making the finding scientifically interesting but contested.
Pineal function research
Epitalon’s original positioning is as a pineal peptide. Animal studies report increased melatonin synthesis and restoration of normal circadian melatonin rhythms in aged rodents (Anisimov et al., 2003). The pineal arm of the research is more reproducible than the telomerase arm.
Longevity research in animal models
Long-term mouse studies from the Khavinson group report increased mean lifespan and reduced spontaneous tumour formation in Epitalon-treated cohorts. The effect size varies (~10-25% lifespan extension across studies). Independent replication in Western labs is limited.
Mechanistic open questions
- No confirmed primary receptor — proposed mechanism involves direct DNA interaction at promoter regions
- Bioavailability of an oral tetrapeptide is questionable (most studies use subcutaneous or intranasal administration)
- Telomerase activation magnitude varies wildly between studies
- Independent replication outside the Russian research programme is sparse
Position in the longevity peptide landscape
Epitalon sits alongside other “geroprotector” peptides researched primarily in Russian labs (Vilon, Thymalin, Cortexin). The research methodology is distinct from Western mainstream — smaller cohorts, longer-term endpoints, less mechanistic precision. This makes the literature interesting as a hypothesis-generating resource but limited as definitive evidence.
Stability and reconstitution
Epitalon is supplied lyophilised. Reconstitution in bacteriostatic water at 1–5 mg/mL is standard. The short tetrapeptide is relatively stable — refrigerated reconstituted Epitalon retains potency for approximately 6 weeks. Avoid freeze-thaw of reconstituted solutions.
Comparison with other longevity research peptides
| Peptide | Primary research target | Replication status |
|---|---|---|
| Epitalon | Telomerase, pineal | Limited outside Russian labs |
| GHK-Cu | ECM, skin repair | Well replicated |
| MOTS-c | Mitochondrial | Growing replication |
| Thymosin Alpha-1 | Immunomodulation | Well replicated |
Research use framing
Epitalon is a research peptide. Claims of human longevity effects are not supported by the kind of controlled trial data that would justify therapeutic positioning. The research is preclinical and observational.
Chempeptides supplies HPLC-verified Epitalon with batch CoA — see the catalogue.
Research use only. Literature summarised above is preclinical.